Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Health
Biotech
Coronavirus
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Pharmalot
STAT+

Mylan payout to CEO will ‘not sit well with investors’

  • Ed Silverman

By Ed Silverman May 3, 2017

Reprints
Mylan
Jeff Swensen/Getty Images

File this under “Tin Ear Syndrome.”

Last year, Mylan chairman Robert Coury received a $97 million pay package. Meanwhile, countless families across America struggled to pay $600 for a package of two EpiPen devices.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Ed Silverman

Ed Silverman

Pharmalot Columnist, Senior Writer

Ed Silverman covers the pharmaceutical industry.

Tags

How a ‘fatally, tragically flawed’ paradigm has derailed the…
How a ‘fatally, tragically flawed’ paradigm has derailed the science of obesity
New on the streets: Gabapentin, a drug for nerve…
New on the streets: Gabapentin, a drug for nerve pain, and a new target of misuse
A quest to explain the whooshing in her head
A quest to explain the whooshing in her head
Biden administration goes easy on Medicare Advantage insurers after…
Biden administration goes easy on Medicare Advantage insurers after intense industry lobbying
European Union drug pricing proposal for the pandemic treaty…
European Union drug pricing proposal for the pandemic treaty generates pushback
Inflation caused a sizable drop in net drug prices…
Inflation caused a sizable drop in net drug prices in late 2022, analysis finds

Comments are closed.

Recommended Stories